Your browser doesn't support javascript.
loading
Hypoxic, glycolytic metabolism is a vulnerability of B-acute lymphoblastic leukemia-initiating cells.
Morris, Vivian; Wang, Dahai; Li, Zhiheng; Marion, William; Hughes, Travis; Sousa, Patricia; Harada, Taku; Sui, Shannan Ho; Naumenko, Sergey; Kalfon, Jérémie; Sensharma, Prerana; Falchetti, Marcelo; Vinicius da Silva, Renan; Candelli, Tito; Schneider, Pauline; Margaritis, Thanasis; Holstege, Frank C P; Pikman, Yana; Harris, Marian; Stam, Ronald W; Orkin, Stuart H; Koehler, Angela N; Shalek, Alex K; North, Trista E; Pimkin, Maxim; Daley, George Q; Lummertz da Rocha, Edroaldo; Rowe, R Grant.
Afiliación
  • Morris V; Stem Cell Program, Boston Children's Hospital, Boston, MA 02115, USA.
  • Wang D; Stem Cell Transplantation Program, Department of Hematology, Boston Children's Hospital, Boston, MA 02115, USA.
  • Li Z; Stem Cell Transplantation Program, Department of Hematology, Boston Children's Hospital, Boston, MA 02115, USA.
  • Marion W; Stem Cell Program, Boston Children's Hospital, Boston, MA 02115, USA.
  • Hughes T; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Harvard Medical School, Boston, MA 02115, USA.
  • Sousa P; Stem Cell Program, Boston Children's Hospital, Boston, MA 02115, USA.
  • Harada T; Cancer and Blood Disorders Center, Dana-Farber Cancer Institute and Boston Children's Hospital, Boston, MA 02115, USA.
  • Sui SH; Harvard Chan Bioinformatics Core, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA.
  • Naumenko S; Harvard Chan Bioinformatics Core, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA.
  • Kalfon J; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
  • Sensharma P; Stem Cell Program, Boston Children's Hospital, Boston, MA 02115, USA; Stem Cell Transplantation Program, Department of Hematology, Boston Children's Hospital, Boston, MA 02115, USA.
  • Falchetti M; Graduate Program of Pharmacology, Center for Biological Sciences, Federal University of Santa Catarina, Florianópolis, Santa Catarina 88040-900, Brazil.
  • Vinicius da Silva R; Graduate Program of Pharmacology, Center for Biological Sciences, Federal University of Santa Catarina, Florianópolis, Santa Catarina 88040-900, Brazil.
  • Candelli T; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
  • Schneider P; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
  • Margaritis T; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
  • Holstege FCP; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
  • Pikman Y; Harvard Medical School, Boston, MA 02115, USA; Cancer and Blood Disorders Center, Dana-Farber Cancer Institute and Boston Children's Hospital, Boston, MA 02115, USA.
  • Harris M; Harvard Medical School, Boston, MA 02115, USA; Department of Pathology, Boston Children's Hospital, Boston, MA 02115, USA.
  • Stam RW; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
  • Orkin SH; Harvard Medical School, Boston, MA 02115, USA; Cancer and Blood Disorders Center, Dana-Farber Cancer Institute and Boston Children's Hospital, Boston, MA 02115, USA; Howard Hughes Medical Institute, Boston, MA 02115, USA.
  • Koehler AN; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
  • Shalek AK; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Institute for Medical Engineering & Science, Department of Chemistry, Massachusetts Institute of Technology, Cambridge, M
  • North TE; Stem Cell Program, Boston Children's Hospital, Boston, MA 02115, USA; Harvard Medical School, Boston, MA 02115, USA.
  • Pimkin M; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Harvard Medical School, Boston, MA 02115, USA; Cancer and Blood Disorders Center, Dana-Farber Cancer Institute and Boston Children's Hospital, Boston, MA 02115, USA.
  • Daley GQ; Stem Cell Program, Boston Children's Hospital, Boston, MA 02115, USA; Harvard Medical School, Boston, MA 02115, USA.
  • Lummertz da Rocha E; Department of Microbiology, Immunology and Parasitology, Federal University of Santa Catarina, Florianópolis Santa Catarina 88040-900, Brazil.
  • Rowe RG; Stem Cell Program, Boston Children's Hospital, Boston, MA 02115, USA; Stem Cell Transplantation Program, Department of Hematology, Boston Children's Hospital, Boston, MA 02115, USA; Harvard Medical School, Boston, MA 02115, USA; Cancer and Blood Disorders Center, Dana-Farber Cancer Institute and Bos
Cell Rep ; 39(4): 110752, 2022 04 26.
Article en En | MEDLINE | ID: mdl-35476984
High-risk forms of B-acute lymphoblastic leukemia (B-ALL) remain a therapeutic challenge. Leukemia-initiating cells (LICs) self-renew and spark relapse and therefore have been the subject of intensive investigation; however, the properties of LICs in high-risk B-ALL are not well understood. Here, we use single-cell transcriptomics and quantitative xenotransplantation to understand LICs in MLL-rearranged (MLL-r) B-ALL. Compared with reported LIC frequencies in acute myeloid leukemia (AML), engraftable LICs in MLL-r B-ALL are abundant. Although we find that multipotent, self-renewing LICs are enriched among phenotypically undifferentiated B-ALL cells, LICs with the capacity to replenish the leukemic cellular diversity can emerge from more mature fractions. While inhibiting oxidative phosphorylation blunts blast proliferation, this intervention promotes LIC emergence. Conversely, inhibiting hypoxia and glycolysis impairs MLL-r B-ALL LICs, providing a therapeutic benefit in xenotransplantation systems. These findings provide insight into the aggressive nature of MLL-r B-ALL and provide a rationale for therapeutic targeting of hypoxia and glycolysis.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Leucemia Mieloide Aguda / Leucemia-Linfoma Linfoblástico de Células Precursoras Límite: Humans Idioma: En Revista: Cell Rep Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Leucemia Mieloide Aguda / Leucemia-Linfoma Linfoblástico de Células Precursoras Límite: Humans Idioma: En Revista: Cell Rep Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos